10-K: Bone Biologics Corporation Reports Full Year 2023 Results, Faces Going Concern Uncertainty

Bone Biologics Corporation's 2023 annual report reveals a significant increase in research and development expenses and a net loss, raising concerns about the company's ability to continue as a going concern.

Summary

• Bone Biologics Corporation, a medical device company focused on bone regeneration, reported its financial results for the year ended December 31, 2023.
• The company experienced a net loss of $8.9 million, a significant increase from the $1.5 million loss in 2022.
• Research and development expenses surged to $6.9 million in 2023, compared to $1.6 million in the previous year, primarily due to the production of the NELL-1 protein for clinical trials.
• General and administrative expenses also increased to $2.5 million from $2.1 million in 2022.
• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• Bone Biologics anticipates needing approximately $5 million to complete first-in-man studies and an additional $24 million for FDA approval of its spine interbody fusion product.
• The company's cash balance at the end of 2023 was $3.0 million, which is expected to fund operations through the second quarter of 2024.
• The company has raised capital through public offerings, including $5 million in June 2023 and $0.6 million in November 2023.
• The company is pursuing regulatory approval for its NELL-1/DBM fusion device, which is intended for use in lumbar spinal fusion.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with a significant increase in losses, a going concern warning, and a short cash runway. While there are some positive aspects, such as the ongoing clinical trial and exclusive license, the overall sentiment is negative due to the financial risks.

Positives

• The company successfully completed a public offering in June 2023, raising $5 million before expenses.
• The company also completed a registered direct offering in November 2023, raising $0.6 million before expenses.
• The company has initiated a first-in-man pilot clinical trial in Australia for its NELL-1/DBM fusion device.
• The company has an exclusive license agreement with UCLA TDG for the NELL-1 technology platform.

Negatives

• The company's net loss increased significantly to $8.9 million in 2023.
• The company's auditor has raised substantial doubt about its ability to continue as a going concern.
• The company's cash balance is expected to fund operations only through the second quarter of 2024.
• The company faces significant competition in the orthobiologic and orthopedic industries.
• The company is dependent on third parties for manufacturing and clinical trials.
• The company has a limited operating history and has incurred losses since inception.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring operating losses.
• The company may not be able to raise sufficient capital to fund its operations and clinical trials.
• The company's product candidates are at an early stage of development and may not be successfully commercialized.
• The company faces significant regulatory hurdles and may not obtain FDA approval for its products.
• The company is subject to product liability risks and may incur substantial liabilities.
• The company's intellectual property may not be sufficient to protect its products from competition.
• The company may face difficulties in enrolling patients in clinical trials.
• The company is dependent on third parties for manufacturing and clinical trials.

Future Outlook

The company anticipates needing approximately $5 million to complete first-in-man studies and an additional $24 million in scientific expenses to achieve FDA approval for a spine interbody fusion indication. The company will continue to attempt to raise additional debt and/or equity financing to fund future operations and to provide additional working capital.

Management Comments

• Management believes that NELL-1 will address unmet clinical challenges for effective bone regeneration, especially in hard healers.
• Management believes that NELL-1's novel set of characteristics, target specific mechanism of action, efficacy, safety and affordability position the product well for application in a variety of procedures.

Industry Context

The company operates in the highly competitive orthobiologic and orthopedic industries, facing competition from large and specialty orthopedic companies, biotechnology companies, academic research institutions, and governmental agencies. The company's NELL-1 growth factor is mechanistically distinct from bone morphogenetic proteins (BMPs) and can minimize complications associated with BMP therapies.

Comparison to Industry Standards

• The company's increased R&D spending is typical for a development-stage biotech company, but the magnitude of the increase is significant.
• The company's net loss is substantial, and the going concern warning from the auditor is a major concern.
• The company's cash runway is short, and it will need to raise significant capital to continue operations.
• The company's reliance on third-party manufacturers and CROs is common in the industry, but it introduces risks.
• The company's intellectual property portfolio is a key asset, but it is subject to challenges and competition.
• Compared to established players like Medtronic, Stryker, and Zimmer-Biomet, Bone Biologics is a small, early-stage company with limited resources.

Management Changes

Corporate Governance

Legal Proceedings

• The company entered into a settlement agreement on January 10, 2024, to resolve a breach of contract and tortious interference lawsuit, agreeing to pay $750,000, with $414,989 paid by the company and $335,011 paid by the insurance carrier.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees may be concerned about the company's ability to continue operations and their job security.
• Customers and partners may be hesitant to engage with the company due to its financial challenges.
• Creditors face increased risk of non-payment due to the company's financial instability.

Next Steps

• The company intends to use the pilot clinical trial data from Australia to enable a future larger U.S. pivotal clinical study, prior to submission of a PMA to the FDA.
• The company will continue to attempt to raise additional debt and/or equity financing to fund future operations and to provide additional working capital.

Key Dates

Keywords

NELL-1, spinal fusion, bone regeneration, medical device, FDA approval, clinical trials, orthobiologics, biotechnology, capital raise, going concern